261 related articles for article (PubMed ID: 30199847)
1. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis.
He LL; Zhang L; Jiang L; Xu F; Fei DS
Int Immunopharmacol; 2018 Nov; 64():223-231. PubMed ID: 30199847
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis.
Wang FP; Liu T; Lan Z; Li SY; Mao H
PLoS One; 2016; 11(11):e0166833. PubMed ID: 27875559
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
Liu Y; Zhang S; Li DW; Jiang SJ
PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
[TBL] [Abstract][Full Text] [Related]
6. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.
Li J; Wang F; Lin C; Du J; Xiao B; Du C; Sun J
J Asthma; 2017 Apr; 54(3):300-307. PubMed ID: 27435534
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
9. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis.
Yan K; Balijepalli C; Sharma R; Barakat S; Sun SX; Falcao S; Druyts E; FitzGerald JM
Immunotherapy; 2019 Dec; 11(17):1491-1505. PubMed ID: 31686556
[No Abstract] [Full Text] [Related]
10. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
Brusselle G; Germinaro M; Weiss S; Zangrilli J
Pulm Pharmacol Ther; 2017 Apr; 43():39-45. PubMed ID: 28159511
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
12. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.
Ramonell RP; Iftikhar IH
Lung; 2020 Feb; 198(1):95-103. PubMed ID: 31894410
[TBL] [Abstract][Full Text] [Related]
13. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials.
Wang FP; Xiong XF; Liu T; Li SY; Cheng DY; Mao H
Clin Rev Allergy Immunol; 2018 Apr; 54(2):318-330. PubMed ID: 27677499
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: systematic reviews].
Gu YL; Pang J; Song JF; Cheng C; Sun ZX
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Nov; 40(11):835-844. PubMed ID: 29320831
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
Liu T; Wang F; Wang G; Mao H
Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
Edris A; De Feyter S; Maes T; Joos G; Lahousse L
Respir Res; 2019 Aug; 20(1):179. PubMed ID: 31395084
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab versus placebo for asthma.
Powell C; Milan SJ; Dwan K; Bax L; Walters N
Cochrane Database Syst Rev; 2015 Jul; (7):CD010834. PubMed ID: 26214266
[TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials.
Cabon Y; Molinari N; Marin G; Vachier I; Gamez AS; Chanez P; Bourdin A
Clin Exp Allergy; 2017 Jan; 47(1):129-138. PubMed ID: 27859832
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
Liu Y; Zhang S; Chen R; Wei J; Guan G; Zhou M; Dong N; Cao Y
Allergy Asthma Proc; 2018 Sep; 39(5):332-337. PubMed ID: 30153886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
